tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MicroPort’s Firehawk® Stent Gains Global Recognition for Transformative Clinical Impact

Story Highlights
  • MicroPort Scientific focuses on innovative cardiovascular devices like the Firehawk® Stent.
  • Firehawk® Stent reduces therapy duration and bleeding risks, gaining global recognition.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
MicroPort’s Firehawk® Stent Gains Global Recognition for Transformative Clinical Impact

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from MicroPort Scientific ( (HK:0853) ) is now available.

MicroPort Scientific Corporation announced that the New England Journal of Medicine and the European Society of Cardiology Congress have published findings from the TARGET-FIRST clinical trial, demonstrating that patients with low-risk myocardial infarction require only one month of dual antiplatelet therapy when implanted with Firehawk® Stents, reducing bleeding complications by 54%. This significant recognition highlights the Firehawk® Stent’s potential to transform global clinical practices, emphasizing its high quality, cost-effectiveness, and accessibility, and reinforcing MicroPort’s commitment to advancing cardiovascular treatment strategies.

The most recent analyst rating on (HK:0853) stock is a Buy with a HK$17.20 price target. To see the full list of analyst forecasts on MicroPort Scientific stock, see the HK:0853 Stock Forecast page.

More about MicroPort Scientific

MicroPort Scientific Corporation is a company focused on developing innovative medical devices and technologies, particularly in the cardiovascular field. Their primary product, the Firehawk® Stent, is a third-generation coronary drug-eluting stent system known for its low restenosis rate and extremely low late stent thrombosis rate. The company aims to ensure that Chinese-made products are recognized globally, backed by robust clinical evidence.

YTD Price Performance: 89.51%

Average Trading Volume: 44,895,730

Technical Sentiment Signal: Buy

Current Market Cap: HK$22.52B

See more insights into 0853 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1